Insight Partners, a venture capital firm, and Clearlake Capital Group, a private investment company, led a $150m Series B round in Iterative Scopes, a company which delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space, with participation from Obvious Ventures, Johnson and Johnson Innovation-JJDC Inc., Eli Lilly, Breyer Capital. “This robust financing comes on the back of an incredibly successful year at Iterative Scopes, reflecting the strength of our technology, team and strategic partnerships. With this investment round, we are relentless in our drive towards narrowing disparities in patient outcomes through the use of artificial intelligence, starting with inflammatory bowel disease and colorectal cancer. The network and support of top tier global investors like Insight Partners and Clearlake Capital alongside our existing investors like Obvious Ventures, JJDC and Eli Lilly will serve to power our progress towards bringing the most advanced computation technology solutions to a field that has significant unmet need,” Jonathan Ng, Iterative Scopes Founder and CEO.